IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Companyâ€™s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotechâ€™s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-08-28	US$0.000100	0.00%	2,551
26-08-27	US$0.000100	0.00%	125
26-08-24	US$0.000100	0.00%	502
26-08-21	US$0.000100	0.00%	2,143
26-08-20	US$0.000100	0.00%	17,266

Delayed Quote OTC Markets

More quotes

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - OTC Markets 13:46:18 2026-08-28 EDT			5-day change	1st Jan Change
0.000100 ^USD	0.00%		0.00%	-99.98%

08-19	Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine	RE
04-05	IO Biotech, Inc.(OTCPK:IOBT.Q) dropped from NASDAQ Composite Index	CI

Market Cap	43.81M 37.82M 35.46M 32.37M 60.9M 4.18B 61.2M 420M 164M 2.11B 164M 161M 7.01B	P/E 2023	-0.95x	P/E 2024	-0.63x
Enterprise Value	-14.31M -12.35M -11.58M -10.57M -19.89M -1.36B -19.98M -137M -53.57M -690M -53.71M -52.54M -2.29B	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	99.69%	Yield 2023 *	-	Yield 2024	-

08-19	Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine	RE
04-05	IO Biotech, Inc.(OTCPK:IOBT.Q) dropped from NASDAQ Composite Index	CI
03-31	IO Biotech, Inc. Filed for Bankruptcy	CI
03-31	Io Biotech Inc - files voluntary chapter 7 bankruptcy petition on March 31, 2026 - SEC filing	RE
03-31	IO Biotech, Inc. Terminates Amy Sullivan as Chief Financial Officer on March 31, 2026	CI
03-31	IO Biotech, Inc. Announces Termination of Mai-Britt Zocca as Chief Executive Officer	CI
03-31	IO Biotech, Inc. Announces Management Changes on March 31, 2026	CI
02-16	CNS Pharmaceuticals, Inc. Announces Executive Appointments, Effective March 2, 2026	CI
01-30	Biotech, Inc. Announces Departure of Qasim Ahmad as Chief Medical Officer and Executive Officer, Effective February 15, 2026	CI
01-30	IO Biotech, Inc. Implements Significant Workforce Reduction as Part of Cost-Containment Measures While Exploring Strategic Alternatives	CI
01-26	IO Biotech Shares Fall After Piper Sandler Downgrade	MT
01-26	Piper Sandler Downgrades IO Biotech to Neutral From Overweight, Adjusts Price Target to $0.50 From $3	MT
01-21	Io Biotech announces exploration of strategic alternatives	RE

01-26	IO Biotech Shares Fall After Piper Sandler Downgrade	MT
01-26	Piper Sandler Downgrades IO Biotech to Neutral From Overweight, Adjusts Price Target to $0.50 From $3	MT
01-08	Morgan Stanley Downgrades IO Biotech to Underweight, Price Target is $0.36	MT
25-09-30	IO Biotech Faces Setback as FDA Opposes Cylembio BLA Submission, Morgan Stanley Says	MT
25-09-30	TD Cowen Downgrades IO Biotech to Hold From Buy	MT

IO Biotech, Inc. Stock

Stocks

IOBTQ

US4497781090

Biotechnology & Medical Research

Valuation : IO Biotech, Inc.

Chart: IO Biotech, Inc.

Latest news : IO Biotech, Inc.

Last Transcript : IO Biotech, Inc.

Analysts' recommendations : IO Biotech, Inc.

Press Releases : IO Biotech, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : IO Biotech, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

02-02	IO Biotech Provides Corporate Update	AQ
01-30	IO Biotech Provides Corporate Update	AQ
01-21	IO Biotech Announces Exploration of Strategic Alternatives	AQ
12-15	IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications	AQ
11-26	IO Biotech Announces Participation in Upcoming December Investor Conferences	AQ

Current month	-50.00%
1 month	-66.67%
3 months	-94.12%
6 months	-99.97%
Current year	-99.98%

1 week	0		0
1 month	0		0
Current year	0		0.7
1 year	0		2.08
3 years	0		2.79
5 years	0		17.88
10 years	0		17.88

Manager	Title	Age	Since
Diane McDowell CTO	Chief Tech/Sci/R&D Officer	-	2021-09-30
Devin Smith CMP	Compliance Officer	58	2023-01-22
Maryann Cimino IRC	Investor Relations Contact	-	2023-03-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
6/5/25	Heidi Hunter	Free	Director	35,144	0.0533%
6/5/25	David Smith	Free	Director	35,144	0.0533%
6/5/25	Helen Collins	Free	Director	35,144	0.0533%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IO BIOTECH, INC.	0.00%	0.00%	-99.99%	-99.99%	7.19K
LONZA GROUP AG	-0.78%	-0.34%	+1.99%	+23.35%	51.14B
REVOLUTION MEDICINES, INC.	-6.00%	-1.82%	+446.48%	+527.28%	47.4B
IQVIA HOLDINGS INC.	-0.24%	+2.23%	+38.64%	+19.52%	43.19B
BEONE MEDICINES AG	-1.55%	-0.66%	+22.19%	+84.83%	42.35B
CELLTRION, INC.	-0.31%	-1.75%	+17.23%	+52.37%	33.23B
MEDPACE HOLDINGS, INC.	-1.79%	-1.96%	+26.86%	+131.18%	17.07B
ASCENDIS PHARMA A/S	-0.58%	-2.71%	-	-	16.38B
EUROFINS SCIENTIFIC SE	-0.88%	-0.63%	+11.05%	+29.54%	14.76B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.66%	+0.02%	+79.05%	+45.47%	14.15B
Average	-0.73%	+0.63%	+60.39%	+90.39%	27.97B
Weighted average by Cap.	-0.64%	+1.12%	+99.46%	+135.52%

	2023	2024
Net sales	-	-
Net income	-86.08M -74.32M -69.67M -63.61M -120M -8.21B -120M -826M -322M -4.15B -323M -316M -13.78B	-95.49M -82.44M -77.28M -70.56M -133M -9.11B -133M -916M -358M -4.61B -358M -351M -15.28B
Net Debt	-141M -121M -114M -104M -196M -13.42B -197M -1.35B -527M -6.79B -528M -517M -22.52B	-58.12M -50.17M -47.03M -42.94M -80.79M -5.54B -81.18M -558M -218M -2.8B -218M -213M -9.3B